Porton Pharma Solutions Ltd. (SHE:300363)
China · Delayed Price · Currency is CNY 23.79
+0.42 (1.80%)
Feb 3, 2026, 3:04 PM CST
Porton Pharma Solutions Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,408 | 2,989 | 3,658 | 7,008 | 3,074 | 2,068 |
Other Revenue | 23.11 | 23.11 | 9.44 | 26.99 | 31.17 | 4.05 |
| 3,431 | 3,012 | 3,667 | 7,035 | 3,105 | 2,072 | |
Revenue Growth (YoY) | 24.51% | -17.87% | -47.87% | 126.55% | 49.87% | 33.56% |
Cost of Revenue | 2,489 | 2,309 | 2,230 | 3,398 | 1,843 | 1,237 |
Gross Profit | 942.1 | 702.62 | 1,437 | 3,636 | 1,262 | 834.99 |
Selling, General & Admin | 504.46 | 557.81 | 693.17 | 807.66 | 386.63 | 303.65 |
Research & Development | 286.38 | 338.49 | 452.23 | 519.51 | 262.02 | 155.19 |
Other Operating Expenses | 24.33 | 10.05 | 35.09 | 58.54 | 14.06 | 5.68 |
Operating Expenses | 843.17 | 926.63 | 1,145 | 1,419 | 706.17 | 468.3 |
Operating Income | 98.93 | -224 | 291.88 | 2,218 | 555.88 | 366.69 |
Interest Expense | -58.13 | -62.06 | -44.15 | -27.73 | -21.7 | -24.39 |
Interest & Investment Income | 10.2 | 24.08 | 57.88 | 22.83 | 14.31 | 33.17 |
Currency Exchange Gain (Loss) | 10.11 | 10.11 | -20.01 | 50.25 | 10.79 | -39.77 |
Other Non Operating Income (Expenses) | 3.09 | -1.64 | -2.53 | -6.73 | -1.5 | -1.3 |
EBT Excluding Unusual Items | 64.21 | -253.5 | 283.07 | 2,256 | 557.77 | 334.4 |
Impairment of Goodwill | - | - | -40.64 | - | - | - |
Gain (Loss) on Sale of Investments | -30.36 | -49.24 | -1.63 | -8.18 | -6.79 | 4.14 |
Gain (Loss) on Sale of Assets | -8.76 | -0.77 | 0.54 | 0.1 | -3.21 | 0.03 |
Asset Writedown | -88.34 | -92.57 | -17.49 | -18.63 | -16.22 | -7.07 |
Other Unusual Items | 49.55 | 22.04 | 22.71 | 16.28 | 17.28 | 32.24 |
Pretax Income | -13.71 | -374.05 | 246.56 | 2,246 | 548.83 | 363.74 |
Income Tax Expense | 60.94 | -8.06 | 71.05 | 309.38 | 73.24 | 40.55 |
Earnings From Continuing Operations | -74.65 | -365.99 | 175.52 | 1,936 | 475.59 | 323.19 |
Minority Interest in Earnings | 73.24 | 78.24 | 91.34 | 68.99 | 48.33 | 1.22 |
Net Income | -1.41 | -287.75 | 266.86 | 2,005 | 523.92 | 324.42 |
Net Income to Common | -1.41 | -287.75 | 266.86 | 2,005 | 523.92 | 324.42 |
Net Income Growth | - | - | -86.69% | 282.78% | 61.49% | 74.84% |
Shares Outstanding (Basic) | 535 | 543 | 545 | 542 | 540 | 532 |
Shares Outstanding (Diluted) | 535 | 543 | 545 | 543 | 540 | 541 |
Shares Change (YoY) | -1.59% | -0.31% | 0.21% | 0.62% | -0.11% | 1.99% |
EPS (Basic) | -0.00 | -0.53 | 0.49 | 3.70 | 0.97 | 0.61 |
EPS (Diluted) | -0.00 | -0.53 | 0.49 | 3.69 | 0.97 | 0.60 |
EPS Growth | - | - | -86.72% | 280.41% | 61.67% | 71.43% |
Free Cash Flow | 172.46 | -85.06 | -500.81 | 1,391 | -296.8 | 110.4 |
Free Cash Flow Per Share | 0.32 | -0.16 | -0.92 | 2.56 | -0.55 | 0.20 |
Dividend Per Share | - | - | 0.487 | 1.106 | 0.193 | 0.121 |
Dividend Growth | - | - | -55.97% | 473.06% | 59.50% | 16.35% |
Gross Margin | 27.46% | 23.33% | 39.19% | 51.69% | 40.64% | 40.30% |
Operating Margin | 2.88% | -7.44% | 7.96% | 31.52% | 17.90% | 17.70% |
Profit Margin | -0.04% | -9.55% | 7.28% | 28.51% | 16.87% | 15.66% |
Free Cash Flow Margin | 5.03% | -2.82% | -13.66% | 19.78% | -9.56% | 5.33% |
EBITDA | 442.17 | 95.9 | 580.68 | 2,452 | 719.86 | 497.81 |
EBITDA Margin | 12.89% | 3.18% | 15.83% | 34.86% | 23.18% | 24.03% |
D&A For EBITDA | 343.24 | 319.9 | 288.8 | 234.54 | 163.98 | 131.12 |
EBIT | 98.93 | -224 | 291.88 | 2,218 | 555.88 | 366.69 |
EBIT Margin | 2.88% | -7.44% | 7.96% | 31.52% | 17.90% | 17.70% |
Effective Tax Rate | - | - | 28.81% | 13.78% | 13.35% | 11.15% |
Revenue as Reported | 3,431 | 3,012 | 3,667 | 7,035 | 3,105 | 2,072 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.